MENU
CRDF
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Cardiff Oncology (CRDF) Earnings Date & Reports
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs... Show more
A.I. Advisor
published Earnings
CRDF is expected to report earnings to rise 5.21% to -14 cents per share on October 29
Q3'26
Est.
$-0.15
Q2'26
Missed
by $0.02
Q1'26
Missed
by $0.05
Q4'25
Beat
by $0.08
Q3'25
Beat
by $0.04
The last earnings report on August 11 showed earnings per share of -14 cents, missing the estimate of -11 cents. With 478.16K shares outstanding, the current market capitalization sits at 68.47M.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information
General Information
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology
Profile
Details
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
31
Web
https://www.cardiffoncology.com